Ann Lab Med.  2013 May;33(3):229-232. 10.3343/alm.2013.33.3.229.

Two Cases of Myeloproliferative Neoplasm with a Concurrent JAK2V617F Mutation and BCR/ABL Translocation without Chronic Myelogenous Leukemia Phenotype Acquisition during Hydroxyurea Treatment

• Park SH
• Chi HS
• Cho YU
• Jang S
• Park CJ
• Kim DY
• Lee JH
• Lee KH

• KMID: 1781334
• DOI: http://doi.org/10.3343/alm.2013.33.3.229

Abstract

No abstract available.

MeSH Terms

Adult
Alleles
Fusion Proteins, bcr-abl/*genetics
Heterozygote
Humans
Hydroxyurea/*therapeutic use
Janus Kinase 2/*genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
Leukocytes, Mononuclear/pathology
Leukocytosis/diagnosis
Male
Middle Aged
Mutation
Myeloproliferative Disorders/drug therapy/*genetics
Phenotype
Splenomegaly/diagnosis
Thrombocytosis/diagnosis
Translocation, Genetic
Fusion Proteins, bcr-abl
Janus Kinase 2
Hydroxyurea

Figure

• 

  Fig. 1 The hematological and molecular characteristics of case 2. (A) A peripheral blood smear revealed tear-drop cells, immature granulocytes, and blasts (Wright stain, ×400). (B) The patient's bone marrow biopsy showed extensive myelofibrosis (H&E stain, ×100), demonstrated by reticulin silver stain (C, ×100) with cellularity of 90% and increased dysplastic megakaryocytes. (D) Mutational analysis of JAK2V617F revealed bands that corresponded to both the mutant and wild-type JAK2 (sized 299 bp and 229 bp, respectively). (E) Along with the myeloproliferative neoplasms (MPNs) diagnosis tests, reverse transcriptase (RT)-PCR analysis of BCR/ABL fusion transcripts was performed and a single 305-bp band, representing the major BCR/ABL translocation (b3a2 type), was obtained.

Reference

1. Tefferi A. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008; 22:14–22. PMID: 17882280.

2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 2008. 4th ed. Lyon: IARC Press.

3. Hummel JM, Kletecka MC, Sanks JK, Chiselite MD, Roulston D, Smith LB, et al. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms. Diagn Mol Pathol. 2012; 21:176–183. PMID: 22847163.

4. Véronèse L, Tchirkov A, Richard-Pebrel C, Ledoux-Pilon A, Fleury J, Chaleteix C, et al. A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm. Leuk Res. 2010; 34:e94–e96. PMID: 19833389.

5. Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia. 2007; 21:1103–1104. PMID: 17301812.

6. Campiotti L, Appio L, Solbiati F, Ageno W, Venco A. JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. Leuk Res. 2009; 33:e212–e213. PMID: 19589593.

7. Kim YK, Shin MG, Kim HR, Yang DH, Cho SH, Lee JJ, et al. Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders. Leuk Res. 2008; 32:993–995. PMID: 18055011.

8. Bee PC, Gan GG, Nadarajan VS, Latiff NA, Menaka N. A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders. Int J Hematol. 2010; 91:136–139. PMID: 20047097.

9. Bocchia M, Vannucchi AM, Gozzetti A, Guglielmelli P, Poli G, Crupi R, et al. Insights into JAK2-V617F mutation in CML. Lancet Oncol. 2007; 8:864–866. PMID: 17913657.

10. Jallades L, Hayette S, Tigaud I, Johnston A, Coiffier B, Magaud JP, et al. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res. 2008; 32:1608–1610. PMID: 18448166.

11. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood. 2005; 106:2920–2921. PMID: 16204151.

12. Mirza I, Frantz C, Clarke G, Voth AJ, Turner R. Transformation of polycythemia vera to chronic myelogenous leukemia. Arch Pathol Lab Med. 2007; 131:1719–1724. PMID: 17979493.

13. Conchon MR, Costa JL, Novaes MM, Dorlhiac-Llacer PE, de Alencar Fischer Chamone D, Bendit I. Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia. Int J Hematol. 2008; 88:243–245. PMID: 18626727.

14. Mizutani S, Kuroda J, Shimizu D, Horiike S, Taniwaki M. Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia. Int J Hematol. 2010; 91:516–521. PMID: 20146031.

15. Xiao X, Zhang Y, Zhang GS, Zheng WL, Xiao L, Liu SF. Coexistence of JAK2V617F mutation and BCR-ABL1 transcript in two Chinese patients with chronic myelogenous leukemia. Acta Haematol. 2012; 127:47–49. PMID: 22025110.

16. Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G, et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood. 2007; 109:4106–4107. PMID: 17449802.

17. Bornhäuser M, Mohr B, Oelschlaegel U, Bornhäuser P, Jacki S, Ehninger G, et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia. 2007; 21:1824–1826. PMID: 17476275.

18. Krämer A. JAK2-V617F and BCR-ABL--double jeopardy? Leuk Res. 2008; 32:1489–1490. PMID: 18439674.

19. Cambier N, Renneville A, Cazaentre T, Soenen V, Cossement C, Giraudier S, et al. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia. 2008; 22:1454–1455. PMID: 18288134.

20. Gattenlohner S, Völker HU, Etschmann B, Einsele H, Müller-Hermelink HK. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2 (V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T). Am J Hematol. 2009; 84:306–307. PMID: 18951468.